If you're interested you'll have to go to the link in the second paragraph.
http://www.medpagetoday.com/Cardiology/Prevention/34349
The possibility that the immunosuppressant drug methotrexate can
prevent major cardiovascular events will be tested in a 7,000-patient
randomized trial funded by the federal government.
Called the Cardiovascular Inflammation Reduction Trial
(CIRT), the 4-year secondary prevention study is sponsored by the
National Heart, Lung, and Blood Institute (NHLBI) and will be led by
Paul Ridker, MD, of Brigham and Women's Hospital and Harvard Medical
School in Boston, as principal investigator.
No comments:
Post a Comment